MARKET

MRKR

MRKR

TAPIMMUNE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.630
-0.110
-4.01%
Opening 10:44 02/24 EST
OPEN
2.720
PREV CLOSE
2.740
HIGH
2.741
LOW
2.630
VOLUME
122.03K
TURNOVER
--
52 WEEK HIGH
9.17
52 WEEK LOW
2.450
MARKET CAP
120.19M
P/E (TTM)
-0.7036
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MRKR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MRKR stock price target is 10.00 with a high estimate of 16.00 and a low estimate of 5.00.

EPS

MRKR News

More
  • Marker Therapeutics to Present at Two Upcoming Investor Conferences
  • PR Newswire · 6d ago
  • Marker up 8% premarket on removal of clinical hold on cell therapy study
  • Seeking Alpha - Article · 02/11 14:25
  • S, TMUS among premarket gainers
  • Seeking Alpha - Article · 02/11 14:18
  • Marker Therapeutics Announces FDA Has Lifted Clinical Hold On Phase 2 AML Trial
  • Benzinga · 02/11 12:11

Industry

Biotechnology & Medical Research
-2.38%
Pharmaceuticals & Medical Research
-2.24%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About MRKR

Marker Therapeutics, Inc., formerly TapImmune Inc., is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. It is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers. It combines a set of licensed technologies, including peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells. Its core technology platforms include TPIV 100/110, a vaccine for the treatment of Human Epidermal Growth Factor receptor 2 (HER2)/neu+ breast cancer that over-expresses HER2/neu; TPIV 200, a vaccine for treating breast and ovarian cancers that over-express Folate Receptor Alpha, and DNA expression vaccine technology (Polystart) for further treating various cancers or infectious disease.
More

Webull offers kinds of Marker Therapeutics Inc stock information, including NASDAQ:MRKR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRKR stock news, and many more online research tools to help you make informed decisions.